A Phase II, Randomized, Multicenter, Double-Blind, Placebo-Controlled, Efficacy, Safety and Tolerability Study of SR57667B in Outpatients With Early Parkinson's Disease.
Phase of Trial: Phase II
Latest Information Update: 07 Jul 2009
At a glance
- Drugs Paliroden (Primary)
- Indications Parkinson's disease
- Focus Therapeutic Use
- Sponsors Sanofi
- 07 Jul 2009 Additional locations identified as reported by ClinicalTrials.gov.
- 22 Dec 2008 Planned number of patients changed from 520 to 564 as reported by ClinicalTrials.gov.
- 22 Dec 2008 Actual end date changed from Feb 2006 to Apr 2006 as reported by Clinicaltrials.gov.